Shuya Li
Director of Clinical Trial Center
Vice Professor of Neurology
Beijing Tiantan Hospital, Capital Medical University.
Relevant International Clinical Trials in Stroke:
1) THALES: a randomized, placebo-controlled, double-blind, event-driven trial to investigate whether ticagrelor combined with aspirin are superior to aspirin alone in preventing stroke or death in patients with non-severe, non-cardioembolic ischemic stroke or high-risk transient ischemic attack
2) NAVIGATE ESUS: an international, randomized, phase III trial enrolled a total of 7213 participants were enrolled from 459 sites to compare the efficacy and safety of rivaroxaban 15mg daily to aspirin 100mg daily for stroke prevention.
3) TRACE-2: a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial in establishing the safety and efficacy of tenecteplase as an alternative to alteplase in the thrombolytic treatment of acute ischemic stroke.
Publication:
1) Li S, Gu HQ, Li H, et al. Reteplase versus Alteplase for Acute Ischemic Stroke. N Engl J Med. 2024;390(24):2264-2273.
2) Wang Y, Li S, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events: a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet 2023.
3) Li S, Wangqin R, Pan Y, et al. Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial. Stroke Vasc Neurol. Published online January 31, 2024. doi:10.1136/svn-2023-002694
4) Shuya Li, et al. Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design, Stroke and Vascular Neurology, 2021.
Abstracts this author is presenting: